The Small Molecule Prefilled Syringes Market, estimated at USD 21.01 Bn in 2025, is expected to exhibit a CAGR of 5.2% and reach USD 29.96 Bn by 2032.
The market growth is driven by increasing demand for innovative and effective drugs across diverse therapeutic areas. Advances in drug discovery, biopharmaceuticals, and digital technologies are improving treatment outcomes and operational efficiency. Supportive regulations, rising R&D investments, and a strong focus on patient-centric care are creating new opportunities for pharmaceutical companies.
Key market players are focusing on adoption of growth strategies such as new product approvals, and this can drive the global small molecule prefilled syringes market growth. For instance, on April 18, 2025, CSL Behring, a pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved a 50 mL/10 g prefilled syringe for Hizentra (Immune Globulin Subcutaneous [Human] 20% Liquid). CSL Behring offers a full range of prefilled syringe sizes to meet the individual needs of people with primary immunodeficiency (PI) or chronic inflammatory demyelinating polyneuropathy (CIDP). Hizentra is the first and only immunoglobulin (Ig) available in a simple, convenient and ready-to-use pre-filled syringe.
Global Small Molecule Prefilled Syringes Market– Impact of Coronavirus (COVID-19) Pandemic
The World Health Organization (WHO) designated the illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan (province of Hubei, China), in the last months of 2025, as "coronavirus disease 2025" or COVID-19. The virus spreads quickly, and had a serious negative impact on the economies, social behaviors, and healthcare of every country in the world.
The COVID-19 pandemic boosted the global small molecule prefilled syringes market, owing to the possible use of these syringes for COVID-19 vaccines. COVID-19 accelerated the development of prefilled syringes, particularly those for low-temperature storage. For example, in September 2025, Becton, Dickinson, and Company (BD) demonstrated the compatibility of its glass prefilled syringes for use with mRNA COVID-19 vaccine injections that require ultralow temperature storage. According to the company, switching from vials to prefilled syringes can reduce the cost and complexity of vaccination delivery. As a result of the COVID-19 pandemic outbreak in 2025, global sales of prefilled syringes skyrocketed. The primary factors driving the market expansion include rising demand for efficient and simple-to-use drug delivery systems, as well as increased efforts by healthcare professionals to eliminate hospital errors.
Global Small Molecule Prefilled Syringess Market: Key Developments
On September 12, 2025, AbbVie Inc., a pharmaceutical company, announced topline results from the phase 3 SEQUENCE clinical trial evaluating risankizumab (SKYRIZI, 600 mg intravenous [IV] induction at weeks 0, 4 and 8 and 360 mg subcutaneous injection [SC] starting at week 12 and every 8 weeks thereafter ) as compared to ustekinumab (STELARA, IV dose at Week 0 and 90 mg SC every 8 weeks thereafter) through Week 48 in patients with moderately to severely active Crohn's disease who have failed one or more anti-TNFs. SKYRIZI is available in a 150 mg/ml pre-filled syringe and pen, a 600 mg/10 ml vial for intravenous infusion and a 180 mg/1.2 ml or 360 mg/2.4 ml vial -Vial available. body injector.